Orchestra BioMed Holdings, Inc. (OBIO) Stock Price & Analysis
Orchestra BioMed Holdings, Inc. (OBIO) closed at USD 5.99 on Wednesday, October 28, 2026, up 3.63% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 5.78; the Oct 28, 2026 session ranged USD 5.69–6.03 on volume of 427,145 shares. Market capitalization is $360.03M, with a 52-week range of USD 3.46–6.5 (NGM). Source: Nexqual, retrieved October 29, 2026 at 07:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OBIO.md
Key facts (OBIO)
- Last four reported quarters (through Jun 30, 2026): revenue $32.0M, net income -$59.0M (-184.6% margin), free cash flow -$59.1M (SEC filings).
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 12.43 (range 9–20).
- Total return with dividends: 1Y +65.9% vs S&P 500 +13.6%; 5Y -39.3% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.4, revenue estimate $104K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OBIO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $3.5M | $2.8M | $2.6M | $33.5M | $32.0M |
| Gross profit | — | $3.3M | $2.6M | $2.4M | $33.3M | — |
| Operating income | -$395K | -$32.7M | -$51.5M | -$64.3M | -$51.8M | -$58.0M |
| Net income | -$379K | -$33.6M | -$49.1M | -$61.0M | -$52.7M | -$59.0M |
| EPS (diluted) | -$0.02 | -$2.24 | -$1.48 | -$1.66 | -$1.11 | — |
| Free cash flow | — | -$29.9M | -$46.2M | -$50.8M | -$49.5M | -$59.1M |
| Gross margin | — | 94.0% | 93.3% | 92.3% | 99.4% | — |
| Operating margin | — | -924.3% | -1866.2% | -2437.5% | -154.7% | -181.4% |
| Net margin | — | -951.3% | -1779.7% | -2313.3% | -157.4% | -184.6% |
| Revenue growth | — | — | -21.9% | -4.4% | +1169.2% | — |
| Cash + short-term investments | $1.8M | $83.7M | $87.5M | $66.8M | $107M | — |
| Total debt | — | — | — | $15.0M | $15.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OBIO)
P/S 11.3x · EV/Sales 8.5x · P/B 18.6x · FCF yield -16.42% · Earnings yield -16.40% · Net cash $89.5M · EV $271M
Analysts (OBIO)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 12.43 (low 9, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Chardan Capital | Maintained | Buy | $20 |
| 2026-09-15 | B. Riley Securities | Target raised | Buy | $10 → $11 |
| 2026-09-10 | BTIG | Upgrade | Neutral → Buy | $10 |
| 2026-08-11 | Piper Sandler | Target raised | Overweight | $9 → $10 |
Total return (dividends reinvested) (OBIO)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +65.9% | -39.3% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +66.2% | -9.5% |
| Volatility (annualized) | 63.4% | 76.5% |
| Max drawdown | -34.8% (Nov 2025→Jan 2026) | -88.7% (Apr 2023→Sep 2025) |
OBIO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.37 | −$0.37 | In line | — |
| — | Quarter ended Dec 31, 2025 | $0.26 | −$0.38 | Beat +$0.64 | — |
| — | Quarter ended Sep 30, 2025 | −$0.40 | −$0.43 | Beat +7.0% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
OBIO recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 1, 2026 | 8-K | Regulation FD disclosure; Other material event “On October 1, 2026, the Company announced that, as of September 30, 2026, 330 patients had been randomized in the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial"), exceeding its previously announced target of 316 randomized patients. The BACKBEAT Trial is evaluating Atrioventricular Interval Modulation Therapy ("AVIM Therapy") in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication. The BACKBEAT Trial is being conducted with Medtronic plc (NYSE: MDT), the Company's strategic…” |
| Sep 8, 2026 | 8-K | Regulation FD disclosure |
| Aug 10, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
OBIO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Integer Holdings Corp (ITGR) | “The Moderato system, comprised of the implantable pulse generator ("IPG") and programmer, was manufactured under an original equipment manufacturer contract by a division of Integer Holdings Corporation ("Integer"), a leading supplier of cardiac rhythm management device components.” |
| Supplier | Sanmina (SANM) | “Currently, the workstation component of our Pure-Vu® System is manufactured by Sanmina Corporation at their facilities in Israel.” |
| Customer | FreeHold Surgical | “We have funded our operations primarily through the issuance of common stock, convertible preferred stock, and warrants, as well as proceeds from the Business Combination, the prior Terumo Agreement and the ROFR and Termination Agreement, borrowings under debt arrangements, the sale of future revenues, and to a lesser extent, revenue from FreeHold products.” |
| Customer | LIGAND PHARMACEUTICALS INC (LGND) | “We accounted for the sale of royalty revenues to Ligand, pursuant to the Royalty Purchase Agreement, in accordance with ASC 470, Debt, which addresses situations in which an entity receives cash from an investor in return for an agreement to pay the investor a specified percentage of the revenue from a contractual right.” |
| Partner | Medtronic plc (MDT) | “We have an exclusive license and collaboration agreement with Medtronic, Inc. (an affiliate of Medtronic plc) ("Medtronic") for the development and commercialization of AVIM Therapy for the treatment of uncontrolled HTN in patients indicated for a cardiac pacemaker (as amended, the "Medtronic Agreement").” |
| Partner | Terumo | “On October 28, 2025, we entered into the Termination and ROFR Agreement with Terumo with respect to Virtue SAB.” |
| Partner | HAEMONETICS CORP (HAE) | “The amount and timing of our future funding requirements are dependent on many factors, including the cost and pace of execution of clinical studies and research and development activities, the strength of results from clinical studies and other research, development and manufacturing efforts, as well as the potential receipt of revenues or other payments or investments under the Medtronic Agreement and/or future …” |
| Partner | Since Orchestra BioMed | “Since Orchestra BioMed, Inc.'s inception, we have devoted the substantial majority of our resources to performing research and development and clinical activities in support of our product development and collaboration efforts.” |
Quoted from the company's 10-K filed Mar 12, 2026.
OBIO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.40 | $-0.38 | −$0.02 | $103,500 | 6 |
| Next quarter (ends Dec 2026) | $-0.41 | $-0.41 | −$0.01 | $106,830 | 6 |
| Current fiscal year (ends Dec 2026) | $-1.52 | $-1.50 | −$0.02 | $451,140 | 6 |
| Next fiscal year (ends Dec 2027) | $-1.51 | $-1.46 | −$0.05 | $600,140 | 6 |
Key Statistics (as of October 29, 2026 at 07:28 UTC)
| Price | USD 5.99 |
|---|---|
| Change | ▲ 3.63% (up) |
| Previous Close | USD 5.78 |
| Open | USD 5.76 |
| Day Range | USD 5.69 – 6.03 |
| 52-Week Range | USD 3.46 – 6.5 |
| Volume | 427,145 shares |
| Market Cap | $360.03M |
| Exchange | NGM |
Technical Analysis (OBIO)
Nexqual's technical model rates OBIO "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 07:28 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.85 (neutral) |
| vs SMA50 | Above (USD 5.68) |
| MACD | 0.01 (positive) |
Analyst Ratings (OBIO)
Wall Street analysts rate OBIO "Buy" based on 7 analysts, with a mean price target of USD 12.43 (range USD 9–20), per Nexqual as of October 29, 2026 at 07:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 12.43 |
| High Target | USD 20 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (OBIO)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $103,500 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.37 vs est -0.37 ▲ beat |
| 2025-12-31 | USD 0.26 vs est -0.38 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.43 ▲ beat |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
Financials & Fundamentals (OBIO)
| Total Revenue | $31.98M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -89.50% |
| Gross Margin | +99.51% |
| Operating Margin | -25404.55% |
| Profit Margin | -184.60% |
| ROE | -397.30% |
| Debt / Equity | 2.41 |
| Current Ratio | 8.26 |
| Total Cash | $109.96M |
| Total Debt | $70.76M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$59.10M (-184.8% of revenue) |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
Financial Health Score (OBIO)
Nexqual rates Orchestra BioMed Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:28 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $110M cash and investments vs $20M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$59M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -305%, ROA -51.0% (last 4 quarters, SEC) |
Ownership (OBIO)
| Insider Ownership | +24.42% |
|---|---|
| Institutional Ownership | +47.77% |
| Shares Outstanding | 60.11M |
| Float | 32.96M |
| Short % of Float | +6.90% |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
Leadership (OBIO)
Orchestra BioMed Holdings, Inc. is led by David P. Hochman, Founder, Chairman of the Board of Directors & CEO, per Nexqual as of October 29, 2026 at 07:28 UTC.
| Founder, Chairman of the Board of Directors & CEO | David P. Hochman |
|---|---|
| Founder, President, COO & Director | Darren R. Sherman |
| Chief Financial Officer | Andrew Lawrence Taylor |
| Executive Vice President of Corporate Development & Strategy | William Reed Little |
| Vice President of Human Resources | Lisa Daniels |
Major Backers & Investors (OBIO)
Notable institutional backers of Orchestra BioMed Holdings, Inc. include RTW Investments LP, Perceptive Advisors Llc, Alyeska Investment Group, L.p., according to Nexqual as of October 29, 2026 at 07:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 15.9% |
| Perceptive Advisors Llc | 8.38% |
| Alyeska Investment Group, L.p. | 1.66% |
| Propel Bio Management, LLC | 1.49% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.07% |
| Fidelity | 0.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.18% |
| Vanguard Group | 3.37% |
| Geode Capital | 1.68% |
| State Street | 0.86% |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
From Orchestra BioMed Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- At the same time, we announced that Medtronic made an additional equity investment in the Company of $11.6 million and committed $20 million in exchange for a secured subordinated promissory note convertible to a capped revenue share credit.
- Beyond regulatory acceleration, the BDD may also support favorable reimbursement pathways, including eligibility for incremental inpatient reimbursement through the New Technology Add-on Payment ("NTAP") and outpatient Transitional Pass-Through payments ("TPT") under the Center for Medicare & Medicaid Services ("CMS") programs.
- Clinical studies performed to date have been conducted using our proprietary Moderato system, a pacemaker system, incorporating AVIM therapy.
Partnerships
- Our strategic collaboration agreement with Medtronic for AVIM Therapy demonstrates our ability to align with a global market leader for the long-term development and commercialization of a product candidate.
- We have an exclusive license and collaboration agreement with Medtronic, Inc. (an affiliate of Medtronic plc) ("Medtronic") for the development and commercialization of AVIM Therapy for the treatment of uncontrolled HTN in patients indicated for a cardiac pacemaker (as amended, the "Medtronic Agreement").
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory compliance is expensive, complex and uncertain, and approvals or certifications can often be denied or significantly delayed. We may not obtain the necessary approvals or certifications and failure to obtain timely regulatory approval or certification, if at all, would adversely affect our business.
- Our medical device products must be manufactured in accordance with federal, state and foreign regulations, and we or any of our suppliers or third-party manufacturers could be forced to recall our installed systems or terminate production if we fail to comply with these regulations.
- Our relationships with physicians, patients and payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations.
- Environmental and health safety laws may result in liabilities, expenses and restrictions on our operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 91.97 | ▼ 0.23% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| PRAX | Praxis Precision Medicines, Inc | USD 285.48 | ▲ 6.69% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt